Clinical Laboratory Experiences During the COVID-19 Pandemic
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciad622 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Romney Humphries und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Centers for Disease Control and Prevention, NIH.
Abstract (Originalsprache)
Not yet 4 years have passed since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, and the practice of infectious diseases (ID) medicine—as conducted by ID specialists and across healthcare—has experienced profound change. This is certainly true for clinical laboratories, which served as vital partners to frontline clinicians throughout the pandemic. As the acute crisis of coronavirus disease 2019 (COVID-19) has shifted into long-term endemicity, the diagnostic landscape remains significantly altered, as are the professionals who served in clinical laboratories throughout this time. In this article, 4 individuals at 1 academic health system reflect on their memories and lessons learned from COVID-19 in their own words. While common threads run throughout these accounts, they reveal complementary perspectives that can differ subtly depending on the individual's particular role and the phase of the pandemic. So, just as clinical laboratorians serve indirectly as caregivers to so many patients, these voices contribute to the diverse clinical narratives of SARS-CoV-2 care. We start broadly with Dr Adam Seegmiller, who reflects on the pandemic from a perspective of global institutional needs. This includes how laboratory members, from leadership to bench workers, fit into a substantial response network and how this participation ultimately broadened their perspectives on the diagnostic mission they serve. “From the perspective of clinical laboratory leaders, the pandemic gave tangible proof of what we always believed but sometimes forget: the diagnostic laboratory plays an essential role in the daily care of patients. Because the laboratory primarily works with samples (eg, blood, tissue) rather than patients themselves, we sometimes feel disconnected from the daily realities of most of our colleagues in healthcare. However, the data we generate are used to make important clinical decisions for almost every patient who receives care in our hospitals and clinics. Some of these decisions are life-changing or even lifesaving. Cloistered in the laboratory and focused on individual tasks, it is easy to lose sight of this reality. The pandemic widened our perspective beyond the laboratory. From the very beginning, institutions across the United States, including our own, established command center teams composed of senior clinical and operational leaders from across the enterprise to share information, make crucial decisions, and coordinate pandemic response efforts. The ability to test patients for SARS-CoV-2 was an essential element to that response, and laboratory leaders were included on the command center team for the entirety of the pandemic’s duration. In regular meetings, we became acutely aware of the laboratory's crucial role in patient care and clinical operations. The pandemic stretched and stressed the laboratory in unprecedented ways. Each subsequent wave of cases and new variants brought new challenges and increasing exhaustion. But the experience revealed lessons that will endure: the diagnostic laboratory is an indispensable component of good clinical care both in ordinary and extraordinary times; collaborative leadership that engages and values the contributions of all parts of an organization with a spirit of cooperation and teamwork is required to survive and thrive under difficult and stressful circumstances; and optimism, creativity, and resilience are all underrated and essential characteristics of effective organizations.” Turning to daily operations, Ms Susan Sefers recalls how many of the greatest challenges facing SARS-CoV-2 diagnostic testing, from the beginning of the pandemic into later waves, were in the realm of laboratory logistics and the grind of management. Faced with enduring demands and systematic limitations, clinical laboratory staff experienced unprecedented stresses, but not without (ultimately) some silver linings to the darker clouds. “On 2 March 2020, Nashville was hit with an EF2/3 tornado in the midst of our laboratory preparing to go live with SARS-CoV-2 testing. In the lab, we were scrambling to pull together a protocol, supplies, and reagents for the Centers for Disease Control and Prevention's laboratory-developed test (LDT) for SARS-CoV-2, while at home, we were without power and hot showers and were experiencing the emotional turmoil of a tornado hitting our city. We went live with our assay on 9 March 2020—the first patient tested positive. By the afternoon, we were overrun with samples. We quickly realized that we needed to perform testing 24 hours a day, 7 days a week, to meet both clinical needs and get through the hundreds (soon thousands) of specimens submitted to us daily for testing. The test itself took hours to run and required that each sample be tested 4 times—once for each of 3 COVID-19 targets and once for a control. Only 24 samples could be run at once. Our technologists spread their shifts out over a 24-hour period, but this solution was clearly not sustainable. Early in the pandemic, it was hard to justify additional hires, as it was impossible to project future cases and testing needs. The technical nature of the LDT obviated our ability to call on nonmolecular trained laboratory staff to help us. State regulations in 2020 required that a Tennessee Medical Laboratory Board–licensed technologists perform patient testing, making it impossible for us to draw on volunteers across our large institution. We soon had to develop a method to triage specimens based on patient’s needs and worked closely with information technology colleagues to assign test priority based on patient symptoms and the scenario. Everyone wanted their tests run “STAT,” but we could perform very few tests quickly at that point. The supply chain was quickly a source of constant stress. Reagents and supplies became harder and harder to obtain. We juggled the need to preorder as many kits as possible with the need to stay within a reasonable budget. On any given day, I was on the phone working with vendors to coordinate testing kits, track down shipments, and keep an eye on our extremely rapid burn rate for reagents. As the volume of specimens increased even further, we obtained first 1, then 2, and ultimately 4 high-throughput instruments. To free up instrument time and staff for COVID testing, we sent many non-COVID–related tests (such as human immunodeficiency virus viral loads) to reference laboratories. These efforts did not truly conserve time as we still had to receive these specimens in the laboratory, accession them, send them to the reference lab, and enter the results into the electronic medical record—all using work-arounds and manual processes. The strain of the pandemic proved too much for many of our technologists, and several resigned. We became entrenched in a market scramble for licensed technologists in our region. Staff who left for higher pay across town were torn by extreme guilt for abandoning their colleagues. We lost nearly a third of our microbiology lab workforce over the course of a month in early 2022. However, in hindsight, there were several positives that came out of the pandemic. We were able to justify equipment that was out of our reach outside a pandemic and were able to get more laboratory space. The value of the laboratory was highlighted institutionally, as was the value of keeping testing near the patient, which enabled a more nimble approach. We developed some of our best talent throughout the pandemic—our team is now extremely resilient and has developed a large tool kit of strategies for any challenge that might be thrown at them. Importantly, work by Vanderbilt University Medical Center and others enabled a change to Tennessee regulations, allowing unlicensed technologists to enter our field, thereby enabling us to have our licensed technologists focus on the work that has them operating at the top of their license and expanding the staffing mix to enable other levels of staff to do low-complexity tasks. Coming out of the pandemic, our ability to care for our patients is strengthened.” The early months of the pandemic were among the most acutely chaotic in the laboratory, as testing had to be rolled out under ever-changing circumstances. Offering perspectives on these heady times is Dr Jonathan Schmitz, who oversaw the development and implementation of the institution's first SARS-CoV-2 diagnostics in 2020. While he acknowledges many of the same challenges described above, he also recalls profoundly collegial and edifying experiences as a clinical professional. “As I reflect back on the early days of the SARS-CoV-2 pandemic when diagnostic testing was one of the few concrete steps to combat the virus, my perspectives even now remain difficult to synthesize under one unified theme. Those months in 2020 progressed at such a frenetic pace for clinical microbiologists, encapsulating what may as well have been a career's worth of professional extremes in the blur of a spring and summer—with experiences across the board from the inspiring to the exhausting! Among many defining memories, I am still touched by profound acts of collaboration and generosity, such as when scientists from across our institution reached out to assist the clinical laboratory in all ways possible (from sorting clinical specimens to opening their own supply rooms). Conversely, I recall the feeling of helplessness in knowing that even our best attempts to ensure testing for our patients could be capriciously uprooted by emergent gaps in the national supply chain or mandated allocations. Admittedly, I still feel pained over the natural psychological strain that fermented under such conditions for laboratory staff—for instance, it was disheartening for all when, in late spring 2020, it became clear that our already Sisyphean efforts would not be lightening any time soon. The spirit of our staff shone through in the gallows humor that emerged as a coping mechanism and generated numerous laughs, even if muffled by surgical masks. To this day, I keep a sign that I first posted on my door in April 2020 quoting from The Divine Comedy: “Lasciate ogni speranza, voi ch'entrate” (a quick online search reveals my tongue-in-cheek implication). Perhaps most personally, I remain indebted to my wife who had to isolate at home with 2 small children (and pregnant with our third) while her husband was forced to disappear from home for several months. If pressed to select a single word to capture my experiences as a clinical microbiologist in 2020, I would have to choose the term vocation. The practice of medicine—as conducted by physicians, nurses, and allied caregivers—is often described as being more than a job but rather a vocation. It is both a science and an art that transcends the individuals who practice it, with their ultimate contributions to society being more important than any other remunerations or accomplishments. Of course, clinical pathology (the umbrella field of clinical microbiology) stands as a distinct medical specialty in its own right. In fact, it is a specialty that is uniquely enriched by the fact that its “attending” practitioners include both medical doctors and PhD scientists. At the same time, I cannot help but feel that the term vocation is not invoked as commonly in clinical pathology/microbiology as it is for other medical fields. This may just be a benign consequence of the fact that we don’t interface directly with the patients we serve, as many of our routine efforts are dedicated to the background logistics of laboratory management and administration. Without some of the more visceral experiences of frontline providers, it can become more challenging to approach daily activities through the prism of a vocation (even when recognizing the importance of this work on a rational level). So perhaps, most of all, this reinforcement of microbiology as a vocation is what the early days of the pandemic accomplished so forcefully in me. With its adrenaline highs and sleep-deprived lows, those months as a laboratory medical director were nothing if not visceral. The impact of our laboratory on the lives in the community was never before so direct, as it was crystal clear that we were laboring in service of the greater good. In fact, it still seems surreal that for a brief period, the world's most sought-after commodity was a service that clinical laboratorians had to provide. (And I think I speak for most clinical laboratorians when I say that our months in that position more than sufficed for a lifetime.) In sum, while the acute days of SARS-CoV-2 are certainly not something that I wish to go through again, I remain profoundly grateful for the opportunity it provided to experience my vocation in such a raw and undiluted manner.” While many hoped that the brunt of COVID-19 would be limited to the early lockdown days, those hopes were dashed as subsequent waves emerged and extended the pandemic's pervasive impact over nearly 2 years. Within diagnostic laboratories, profound challenges reemerged with each subsequent variant, even as the rest of the world desperately longed to return to normal. Reflecting on these experiences is Dr Romney Humphries, who had to steer through interconnected challenges that extended well beyond SARS-CoV-2 testing itself into the various other dimensions of laboratory medicine. While these long-haul challenges were among the most trying mentally and emotionally, networks of support and coordination once more allowed the laboratory to continue supporting massively diverse aspects of clinical care. “Many days, the first thing I did when I got to work during the Omicron surge was to sit in front of my computer and cry for 5 minutes—a small release valve that gave me the endurance to confront another emotionally exhausting day. Over the course of the pandemic, the daily grind of pleading with diagnostic vendors for reagents, consumables, and instruments and encouraging a burnt-out staff of laboratory professionals had been stressful, but nothing compared with Omicron. I started my role as Division Director for Laboratory Medicine in the fall of 2022. Prior to this, I was the microbiology laboratory director. Not 4 months into this new role, Omicron gave me a pressure-cooker course on how to deal with the spectrum of challenges, from clinical testing fallout and recovery to faculty departures. In the early pandemic, I was able to rely on my years of experience as a clinical microbiologist to handle the day-to-day challenges, not to mention a large support group of like-minded (and situated!) clinical microbiologists. We developed co-coping strategies, trading ridiculous stories on how we begged and borrowed to make ends meet. My good friend drew up plans to house a sheep in her backyard. (Throughout the pandemic, many microbiology reagents became scarce as companies pivoted to COVID-19 production. Staples, such as sheep's blood agar plates, the backbone of every bacterial culture in the lab, were often hard to come by.) I pulled on every business connection I had from my time in the diagnostic industry, including ones in China, to obtain testing reagents. However, the breadth and severity of challenges associated with laboratory testing became so much more pressing during Omicron. We experienced critical shortages in our blood bank as blood donors and the staff at donor centers became more and more scarce. I will never forget a low day when a regional hospital transferred a woman with postpartum hemorrhage to us as they did not have sufficient blood to care for her. We performed 3 cycles of massive transfusion protocol but were unable to save her. The process used three-quarters of our O-positive blood and left us in an uncomfortable position as we pled with our vendors for an emergency release of blood products. Should we have stopped transfusions for this patient sooner? I couldn’t help but feel we were further losing our ability to care for patients beyond those afflicted with COVID-19 (which was horrible enough in its own right). Calls to our blood suppliers were not fruitful—everyone was in the same boat. During Omicron, inexorable reagent supplies left us short on every front in the laboratory. Images of tanker ships in gridlock at the Port of Los Angeles were shared in our command center calls. No ships were entering; no supplies were being delivered. We were short of phlebotomy needles, reagents, and consumables (all presumably sitting on a ship in Long Beach, California). Further COVID-19 polymerase chain reaction reagent allocations crushed us at a time when we were testing more patients than ever. Our primary blood collection tube for chemistry testing, lithium heparin, became unavailable. A rapid pivot to alternative tube types required that we discontinue all add-on testing, as specimen stability when collected in alternative tubes was unacceptable. Turnaround times also increased, as these tubes required 30 minutes of clotting time prior to use. Instruments went down. Alternate vendors offered scandalous multimillion-dollar contracts for SARS-CoV-2 testing supplies, with a promise of par levels that only partially met our needs, but only if we signed quickly and committed for 3 years at a minimum. The thought that we might still be doing testing at the levels required during Omicron in 3 years nearly undid me (we did not sign). While it's hard in retrospect to untangle the emotions I experienced throughout Omicron, I recall feeling an overwhelming respect and gratitude for my colleagues at all levels. I have never experienced an entire institution pulling together in the way we did. There was no blame, just problem-solving. Protocols were adapted to address blood, reagent, and supply shortages. Blood donor were and additional vendors were COVID-19 testing were up to draw volume from the hospital laboratory. strategies were used for Instruments were sent to us on from enterprise partners to ensure that patients could be for testing. from across the hospital and came to help the laboratory. On any given day, could from our to the of laboratories, working in with the of volunteers in and efforts from health information hospital and were to ensure that we could care for our patients. The of this pandemic me of lives more than a lives and many and colleagues out and the But it is not all The the hospital in the laboratory was The resilience and of a large group of individuals to care for our patients me daily I this
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Romney Humphries
Förderung
- NIAID NIH HHS
- Centers for Disease Control and Prevention
- NIH
Zitieren
APA
Humphries, R., Sefers, S., Schmitz, J., & Seegmiller, A. (2024). Clinical Laboratory Experiences During the COVID-19 Pandemic. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad622
Vancouver
Humphries R, Sefers S, Schmitz J, Seegmiller A. Clinical Laboratory Experiences During the COVID-19 Pandemic. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad622
BibTeX
@article{Humphries2024,
author = {Humphries, Romney and Sefers, Susan and Schmitz, Jonathan and Seegmiller, Adam},
title = {Clinical Laboratory Experiences During the COVID-19 Pandemic},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciad622}
}
EUVIMED